Home › Compare › GWLLF vs ABBV
GWLLF yields 4.02% · ABBV yields 3.06%● Live data
📍 GWLLF pulled ahead of the other in Year 2
Combined, GWLLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GWLLF + ABBV for your $10,000?
Great Wall Motor Company Limited researches and develops, manufactures, and sells automobiles, and automotive parts and components in China, Russia, South Africa, Australia, Saudi Arabia, Chile, and internationally. The company offers pick-up trucks, SUVs, sedans, and energy vehicles primarily under the Haval, WEY, ORA, Tank, and Great Wall Pickup brand names; and unmanned vehicles. It also provides auto molds; new energy vehicle transmission and electric drive system; repairs automobiles; and transports general goods, as well as daily cargo transportation services. In addition, the company offers investment and financing, buildings rental, logistics, business information consultation, scrap car recycling and dismantling, finance leasing, asset management, equity investment, technology information and development, trade consultation, international trade, financial guarantee, and after-sales services, as well as automotive technology research, development, and technical consultation services. Further, it processes, recycles, and sells waste and used materials; and sells lubricants. Additionally, the company engages in the wholesale and retail of car accessories. It also exports its products. Great Wall Motor Company Limited was formerly known as Baoding Great Wall Motor Company Limited and changed its name to Great Wall Motor Company Limited in May 2003. The company was founded in 1984 and is headquartered in Baoding, China. Great Wall Motor Company Limited is a subsidiary of Baoding Innovation Great Wall Asset Management Company Limited.
Full GWLLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.